PURPOSE: Despite becoming the preferred surgical technique for malignant pleural mesothelioma, pleurectomy/decortication has received few prospective clinical trials. Therefore, the Japan Mesothelioma Interest Group conducted a prospective multi-institutional study to evaluate the feasibility of neoadjuvant chemotherapy followed by … [Read more...]
Drug Combo Promising in Rare Mesothelioma
A combination of atezolizumab (Tecentriq) and bevacizumab appeared effective and safe in patients with advanced malignant peritoneal mesothelioma, according to results from a small single-arm trial. The combination achieved an objective response rate (ORR) of 40% in patients who had progressed on or were resistant to prior platinum-pemetrexed … [Read more...]
A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion
Background: Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that originates from pleural mesothelial cells. In recent years, with the development of asbestos-related industries and the increase in air pollution, its incidence has been increased. The incidence of pulmonary embolism combined with sarcomatoid MPM is very low and the … [Read more...]
Osteopontin, GLUT1 and Ki-67 expression in malignant peritoneal mesothelioma: prognostic implications
Background: Malignant peritoneal mesothelioma is the most common primary peritoneal neoplasm. The only universally recognised pathological prognostic factor is histopathological subtype. Prognostic markers based on patient features and clinical stages have been disappointing. Aims: To assess the prognostic role of several clinicopathological … [Read more...]
The association between pleural fluid exposure and survival in pleural mesothelioma
Background: Most patients with malignant pleural mesothelioma (MPM) present with malignant pleural effusion (MPE). There is in vitro evidence that MPE may not be a simple bystander of malignancy, but potentially has biological properties improving cancer cell survival and promoting cancer progression. If this is the case, MPE management may need … [Read more...]
Vinorelbine extends PFS in relapsed malignant pleural mesothelioma
Vinorelbine combined with active supportive care conferred superior [ progression-free survival (PFS) ] compared with active supportive care alone among patients with relapsed malignant pleural mesothelioma, according to phase 2 study results. “All patients with malignant pleural mesothelioma eventually relapse following standard … [Read more...]
Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions
Objectives: Medical management based on palliative chemotherapy is currently the standard of care in malignant pleural mesothelioma (MPM). Median survival of 12–16 months has been reported with modern chemotherapy regimens with or without anti-angiogenic agents. Multimodality therapy incorporating cytoreductive surgery, systemic chemotherapy … [Read more...]
Nivolumab prolongs PFS, OS in relapsed malignant mesothelioma
Nivolumab significantly prolonged PFS and OS compared with placebo for patients with [ relapsed mesothelioma ], according to findings presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer. “Mesothelioma is predominately a disease that is not suitable for surgery and is one for which chemotherapy has … [Read more...]
Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma
Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of tumor size in only a minority of patients. Predicting response to chemotherapy in patients with MPM by using a genetic marker would, therefore, enable patient … [Read more...]
Incidence of mesothelioma and asbestosis by occupation in a diverse workforce
Objective: We sought to characterize detailed patterns of mesothelioma and asbestosis incidence in the workforce as part of an occupational disease surveillance program in Ontario, Canada. Methods: The Occupational Disease Surveillance System (ODSS) cohort was established using workers’ compensation claims data and includes 2.18 million workers … [Read more...]
- 1
- 2
- 3
- …
- 23
- Next Page »